Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

Inclusion Criteria: * Diagnosis of chronic myeloid leukemia in chronic phase (CML-CP) associated with BCR-ABL1 quantifiable by RQ-PCR (IS) * No other current or planned anti-leukemia therapies excluding hydroxyurea treatment for up to two months. * ECOG Performance status 0,1, or 2 * Adequate organ function as defined by: Total bilirubin \< 1.5 x ULN (ULN = upper limit of normal in a local institution lab) in absence of Gilbert genotype; ASAT and ALAT \< 2.5 x ULN. Creatinine \< 2x ULN. Potassium, magnesium and phosphate not below LLN (LLN= lower level of normal) * Life expectancy of more than 12 months in the absence of any intervention * Patient has given written informed consent to participate in the study Exclusion Criteria: * Prior accelerated phase or blast crisis * Uncontrolled or significant cardiovascular disease, including any of the following: * A myocardial infarction within 6 months * Uncontrolled angina within 3 months * Congestive heart failure within 3 months * Diagnosed or suspected congenital long QT syndrome * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointe) * Prolonged QTcF interval \> 450 msec on pre-entry ECG * Atypical BCR-ABL1 transcript not quantifiable by RQ-PCR. * Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation) Severe and/or life-threatening medical disease including acute liver disease * History of significant congenital or acquired bleeding disorder unrelated to cancer * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dasatinib * Patients actively receiving therapy with strong CYP3A4 inhibitors and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug * Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug * Female patients who are: pregnant, breast feeding or potentially fertile without a negative pregnancy test prior to baseline or unwilling to use contraception on trial * Previous history of pericarditis or pleuritis * History of non-compliance, abuse of alcohol, illicit drugs, severe psychiatric disorders or other inability to grant informed consent. * Current treatment for depression. * Hypersensitivity to any interferon preparation; * Autoimmune hepatitis or a history of autoimmune disease; * Pre-existing thyroid disease unless it can be controlled with conventional treatment; * Epilepsy and/or compromised central nervous system (CNS) function; * HCV/HIV patients